Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zydus
Pharma
Akeso-Summit, BIOSECURE, Candid and more—Fierce Pharma Asia
Akeso and Summit's ivonescimab handily beat Keytruda in a China phase 3 study. The House passed the BIOSECURE Act. Candid emerged with $370 million.
Angus Liu
Sep 13, 2024 8:53am
Zydus hit with FDA warning letter flagging glass contamination
Sep 11, 2024 11:42am
Astellas, AstraZeneca, Glenmark and more—Fierce Pharma Asia
Sep 6, 2024 9:00am
FDA scrutiny of India’s Zydus results in warning letter
Sep 3, 2024 8:40am
FDA issues another Form 483 reprimand for drugmaker Zydus
May 6, 2024 12:09pm
Endo hits Zydus with patent suit over generic version of Chantix
Aug 11, 2023 10:45am
